Loading...
Market
What will be the outcome of CagriSema trials in other regions by the end of 2025?
2
Resolution / Starting Odds
Achieve target weight loss in all regions • 25%
Achieve target weight loss in some regions • 25%
No region achieves target weight loss • 25%
Trials discontinued • 25%
Official trial results published by Novo Nordisk or in scientific journals
Story
Novo Nordisk Shares Plunge 29% After CagriSema Falls Short of 25% Weight Loss Target
Dec 20, 2024, 12:30 PM
Novo Nordisk announced that its experimental obesity drug CagriSema achieved a 22.7% weight loss in adults with obesity or overweight in the REDEFINE 1 Phase 3 trial after 68 weeks. While this result demonstrated superior weight loss compared to semaglutide 2.4 mg (16.1%), cagrilintide 2.4 mg (11.8%), and placebo (2.3%), it fell short of the company's anticipated target of 25% weight loss. Following the announcement, Novo Nordisk's shares plunged as much as 29%, marking the largest single-day drop on record for the company and erasing over $140 billion in market value.
View original story
Similar markets
Positive results with MRD-negative CR • 25%
Mixed results • 25%
Negative results • 25%
Trial discontinued • 25%
Seek further trials • 25%
Submit for regulatory approval • 25%
Discontinue development • 25%
Partner with another company • 25%
Meets primary endpoint • 25%
Fails primary endpoint • 25%
Mixed results • 25%
Trial not completed by end of 2025 • 25%
Convicted • 25%
Acquitted • 25%
Case dismissed • 25%
Other outcome • 25%
Ineffective dosage • 25%
Patient non-compliance • 25%
Adverse side effects • 25%
Other • 25%
Convicted • 25%
Acquitted • 25%
Mistrial • 25%
Other outcome • 25%
Yes • 50%
No • 50%
Most regulations upheld • 33%
Most regulations overturned • 33%
Mixed outcomes • 34%
Successful with expected results • 25%
Partially successful • 25%
Unsuccessful • 25%
Results inconclusive • 25%
Successful with significant results • 25%
Moderate success with some positive results • 25%
No significant results • 25%
Trial halted or inconclusive • 25%